Filip Janku - Net Worth and Insider Trading

Filip Janku Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Filip Janku owns 1 companies in total, including Monte Rosa Therapeutics Inc (GLUE) .

Click here to see the complete history of Filip Janku’s form 4 insider trades.

Insider Ownership Summary of Filip Janku

Ticker	Comapny	Transaction Date	Type of Owner
GLUE	Monte Rosa Therapeutics Inc	2021-06-23	Chief Medical Officer

Filip Janku Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Filip Janku Ownership Network

Ownership Network List of Filip Janku

No Data

Ownership Network Relation of Filip Janku

Filip Janku Owned Company Details

What does Monte Rosa Therapeutics Inc do?

Who are the key executives at Monte Rosa Therapeutics Inc?

Filip Janku is the Chief Medical Officer of Monte Rosa Therapeutics Inc. Other key executives at Monte Rosa Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , Principal Accounting Officer Edmund Dunn , and General Counsel Philip Nickson .

Monte Rosa Therapeutics Inc (GLUE) Insider Trades Summary

Over the past 18 months, Filip Janku made no insider transaction in Monte Rosa Therapeutics Inc (GLUE). Other recent insider transactions involving Monte Rosa Therapeutics Inc (GLUE) include a net sale of 2,817 shares made by Edmund Dunn , and a net sale of 567,213 shares made by Versant Venture Capital Vi, L.p. .

In summary, during the past 3 months, insiders sold 568,823 shares of Monte Rosa Therapeutics Inc (GLUE) in total and bought 0 shares, with a net sale of 568,823 shares. During the past 18 months, 570,030 shares of Monte Rosa Therapeutics Inc (GLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 570,030 shares.

Monte Rosa Therapeutics Inc (GLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monte Rosa Therapeutics Inc Insider Transactions

No Available Data

Filip Janku Mailing Address

Above is the net worth, insider trading, and ownership report for Filip Janku. You might contact Filip Janku via mailing address: Monte Rosa Therapeutics, Inc., 40 Guest Street, Boston Ma 02134.

Discussions on Filip Janku

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.